Ultragenyx Pharmaceutical logo

Ultragenyx PharmaceuticalNASDAQ: RARE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

31 January 2014

Next earnings report:

14 February 2025

Last dividends:

N/A

Next dividends:

N/A
$4.25 B
-29%vs. 3y high
88%vs. sector
-vs. 3y high
-vs. sector
-88%vs. 3y high
93%vs. sector
-54%vs. 3y high
74%vs. sector

Price

pre-market | 62 min ago
$46.00-$2.00(-4.17%)

Dividend

No data over the past 3 years
$139.49 M$146.90 M
$139.49 M-$133.52 M

Analysts recommendations

Institutional Ownership

RARE Latest News

Ultragenyx: Ready For More Growth After Q3 Earnings Beat
seekingalpha.com12 November 2024 Sentiment: POSITIVE

Ultragenyx's strong Q3 earnings report, with a 42% YoY revenue increase, has reignited my interest in initiating a starter position in RARE. The company's promising pipeline, including late-stage programs like Setrusumab and DTX401, presents multiple catalysts for future growth and higher valuation. Ultragenyx's $825M cash position and path to profitability by 2026 suggest financial stability, potentially avoiding the need for extensive dilutive financing.

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Transcript
seekingalpha.com05 November 2024 Sentiment: POSITIVE

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Joshua Higa - VP, IR Emil Kakkis - CEO and President Erik Harris - CCO Howard Horn - CFO Eric Crombez - CMO Conference Call Participants Chris Raymond - Piper Sandler Tazeen Ahmad - Bank of America Malcolm Kuno - JPMorgan Gena Wang - Barclays Lydia Erdman - Goldman Sachs Maury Raycroft - Jefferies Mehdi Goudarzi - Truist Securities Yaron Werber - TD Cowen Yigal Nochomovitz - Citi Thomas Yip - H.C. Wainwright Jack Allen - Baird Joe Schwartz - Leerink Partners Michael Riad - Morgan Stanley Kristen Kluska - Cantor Fitzgerald Dae Gon Ha - Stifel Operator Good afternoon and welcome to the Ultragenyx Third Quarter 2024 Financial Results Conference Call.

Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics
zacks.com05 November 2024 Sentiment: POSITIVE

While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates
zacks.com05 November 2024 Sentiment: POSITIVE

Ultragenyx (RARE) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $2.23 per share a year ago.

RARE's Wilson Disease Candidate Betters Standard Therapy in Study
zacks.com04 October 2024 Sentiment: POSITIVE

Ultragenyx reports superior efficacy of UX701 for Wilson disease compared with standard therapy from the Stage 1 cohorts of its pivotal phase I/II/III study.

Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
globenewswire.com03 October 2024 Sentiment: POSITIVE

NOVATO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today reported that the Phase 1/2/3 Cyprus 2+ study of its UX701 gene therapy has demonstrated meaningful clinical activity as well as improvements in copper metabolism in Stage 1. Multiple responders have completely tapered off of standard-of-care treatment with responses seen in all three dose cohorts. The company plans to enroll an additional cohort in Stage 1 at a moderately increased dose and with an optimized immunomodulation regimen to enhance the efficiency and efficacy of the gene therapy, with the objective of having the majority of patients come off of standard-of-care treatment before selecting a dose for the randomized placebo-controlled stage of the study.

Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
globenewswire.com26 September 2024 Sentiment: POSITIVE

NOVATO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it will present seven abstracts related to its ongoing late-stage program evaluating setrusumab (UX143) and osteogenesis imperfecta (OI), including a late-breaker oral presentation of the 14-month data from the Phase 2/3 Orbit study, at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting. The meeting is being held September 27-30, 2024, in Toronto, Canada.

AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE
prnewswire.com23 September 2024 Sentiment: POSITIVE

THOUSAND OAKS, Calif. , Sept. 23, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:30 p.m.

Ultragenyx to Participate in Investor Conferences in September
globenewswire.com29 August 2024 Sentiment: POSITIVE

Morgan Stanley 22 nd Annual Global Healthcare Conference on September 4 Cantor Global Healthcare Conference on September 17 Bank of America Global Healthcare Conference on September 18 NOVATO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor conferences.

Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective
seekingalpha.com22 August 2024 Sentiment: POSITIVE

Ultragenyx develops therapies for rare genetic diseases, with a portfolio including Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company's promising pipeline targets severe diseases like osteogenesis imperfecta and Angelman syndrome, and it has progressed well in clinical trials. The company's financials show a strong cash position but a high P/B and P/S ratios, as well as significant future royalty liabilities on Crysvita.

  • 1(current)
  • 2
  • 3

What type of business is Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company headquartered in Novato, California, specializing in the development and implementation of new drugs for the treatment of severe rare genetic diseases. It was founded in 2010. The company focuses its efforts on developing drugs for patients with diseases that have no treatment options. Today, there are many rare genetic diseases that do not have approved therapies. The company's product portfolio includes two commercially approved products, as well as several candidates at various stages of clinical trials, which can be divided into three categories: biologics, gene therapy products, and small molecules.

What sector is Ultragenyx Pharmaceutical in?

Ultragenyx Pharmaceutical is in the Healthcare sector

What industry is Ultragenyx Pharmaceutical in?

Ultragenyx Pharmaceutical is in the Biotechnology industry

What country is Ultragenyx Pharmaceutical from?

Ultragenyx Pharmaceutical is headquartered in United States

When did Ultragenyx Pharmaceutical go public?

Ultragenyx Pharmaceutical initial public offering (IPO) was on 31 January 2014

What is Ultragenyx Pharmaceutical website?

https://www.ultragenyx.com

Is Ultragenyx Pharmaceutical in the S&P 500?

No, Ultragenyx Pharmaceutical is not included in the S&P 500 index

Is Ultragenyx Pharmaceutical in the NASDAQ 100?

No, Ultragenyx Pharmaceutical is not included in the NASDAQ 100 index

Is Ultragenyx Pharmaceutical in the Dow Jones?

No, Ultragenyx Pharmaceutical is not included in the Dow Jones index

When was Ultragenyx Pharmaceutical the previous earnings report?

No data

When does Ultragenyx Pharmaceutical earnings report?

The next expected earnings date for Ultragenyx Pharmaceutical is 14 February 2025